atezolizumab + trastuzumab + capecitabine + oxaliplatin

Atezolizumab + trastuzumab + capecitabine + oxaliplatin is a combination regimen under investigation for the treatment of **human epidermal growth factor receptor 2 (HER2/ERBB2)–positive locally advanced resectable gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma**. This regimen combines four components: - **Atezolizumab**: a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing immune system recognition and attack of cancer cells. - **Trastuzumab**: a monoclonal antibody directed against HER2 (ERBB2), a receptor overexpressed in certain cancers, providing targeted anti-tumor activity. - **Capecitabine**: an oral prodrug of 5-fluorouracil (5-FU) which interferes with DNA synthesis in cancer cells (antimetabolite). - **Oxaliplatin**: a platinum-based chemotherapeutic agent causing DNA crosslinks and apoptosis in cancer cells. In a phase 2 clinical trial (NCT04661150), this combination demonstrated a significantly higher pathological complete response rate compared to trastuzumab + XELOX alone (38.1% vs 14.3%), with manageable safety profile and no new safety signals observed[1][3][4][9][10]. The regimen is administered with atezolizumab, trastuzumab, and oxaliplatin given intravenously, and capecitabine given orally in specified cycles around surgery[4][7]. Main indication explored is **HER2-positive gastric and GEJ cancer**.

Other names

atezolizumab + trastuzumab + XELOX